1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6F3FF9E8D7E65308300258ADA0025ED0E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-rare-disease-field-medical-excellence-europe-establishing-standards-high-performance-impact?opendocument
18
19opendocument
2034.236.191.0
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Benchmarking Rare Disease Field Medical Excellence in Europe: Establishing Standards for High Performance & Impact

ID: 5796


Features:

9 Info Graphics

14 Data Graphics

110+ Metrics

7 Narratives


Pages/Slides: 28


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Benchmarking Rare Disease Field Medical Excellence in Europe: Establishing Standards for High Performance & Impact”

STUDY OVERVIEW

Europe's rare disease market presents a complex landscape shaped by diverse healthcare systems, regulatory frameworks, and cultural nuances across different countries. Amidst this complexity, optimizing the efficiency of field medical teams is crucial for rare disease manufacturers aiming to meet the unique needs of various influential stakeholders in this region.

Best Practices, LLC undertook this benchmarking research to establish standards for high field medical performance and impact in Europe's rare disease market. Our study provides strategic insights tailored to improve KOL interactions, measure MSL performance, and strategically align staffing footprints.


KEY TOPICS

  • Effective Rare Disease Field Performance Metrics in Europe
  • Building a Rare Disease Field Medical Excellence Framework
  • Target and Engagement Levels of Rare Disease KOLs in Europe
  • Average Time Spent by Rare Disease MSLs on KOL Interactions and Internal Activities in Europe
  • Rare Disease Field Medical Staffing Footprint in Europe
  • Key Insights and Lessons Learned for Measuring the Impact of Rare Disease MSLs in Europe

KEY METRICS

  • Europe field scorecard: Benchmarking rare disease engagements
  • Average number of tiered vs. non-tiered KOLs per rare disease MSL in Europe
  • Monthly KOL and F2F interactions in Europe – Rare disease segment
  • Weighting criteria for various interaction types on the rare disease MSL scorecard (Europe)
  • Metrics for engaging non-tiered rare disease KOLs in Europe
  • Average rare disease MSL time in the field (days per year) in Europe
  • Percentage of rare disease MSL time spent on external, internal, and logistics activities in Europe
  • Weekly rare disease MSL time allocation for each activity stream in Europe
  • Percentage of overall rare disease targets classified as KOLs, HCPs, payers, or other external stakeholders in Europe
  • Rare disease field medical staffing footprint in Europe

SAMPLE KEY FINDINGS

  • Emphasis on F2F Interactions in Europe: Rare diseases field medical teams in Europe assign higher value to Face-to-Face (F2F) interactions, recognizing their significant impact on the overall MSL scorecard. This emphasis underscores the profound impact such engagements wield in fostering meaningful connections and driving key metrics forward.

METHODOLOGY

Best Practices, LLC collated performance data and insights from field medical executives from rare disease companies around the world through a custom benchmark survey. Focused on rare disease field medical operations in Europe, the research drew insights from a diverse range of respondents.


Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks for maximal alignment with varied portfolio considerations.

The final study draws on 448 survey responses, representing a benchmark class of over 100 biopharma manufacturers.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.